983 completed, 81 terminated, 80 unknown, 64 recruiting. 1290 Phase 3, 107 Phase 2.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 1290 | Completed 983, Terminated 81, Unknown 80, Recruiting 64, Withdrawn 43, Not yet recruiting 19, Active not recruiting 16, Enrolling by invitation 3, Suspended 1 |
| Phase 2 | 107 | Completed 72, Unknown 13, Withdrawn 8, Terminated 7, Recruiting 3, Active not recruiting 2, Not yet recruiting 2 |
Follow Lung Diseases, Obstructive: new trials by email Literature Review of Lung Diseases, Obstructive trials Research Report on Lung Diseases, Obstructive
Trials (filtered) newest first · largest first
All 1,290 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Verducatib, Placebo matching verducatib - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | 1800 | 2027-03-10 | 2026-10-30 |
Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)
Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | 1252 | 2027-01-30 | 2026-10-26 |
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
CHF5993 100/6/12.5 μg pMDI HFA-152a, Seretide Evohaler - Asthma | Phase 3 | Not yet recruiting | 700 | 2026-11-16 | 2026-10-05 |
Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)
Ensifentrine, Placebo, Standard of Care (SOC) - Pulmonary Disease, Chronic Obstructive | Phase 3 | Not yet recruiting | 2136 | 2026-10-23 | 2026-10-15 |
Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | | 2026-10-01 | 2026-10-23 |
A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Placebo, REGEND001 - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | 102 | 2026-10-01 | 2026-09-24 |
A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma
tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | 1100 | 2026-09-30 | 2026-10-09 |
A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of Time
Tilrekimig - Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | 1360 | 2026-09-21 | 2026-09-24 |
A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
Lunsekimig - Chronic Obstructive Pulmonary Disease | Phase 3 | Enrolling by invitation | 1508 | 2026-09-16 | 2026-10-21 |
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
GSK5784283, Placebo, Standard of care - Pulmonary Disease, Chronic Obstructive | Phase 3 | Recruiting | 624 | 2026-09-11 | 2026-09-25 |
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Belumosudil, Best available therapy (BAT) - Chronic Graft Versus Host Disease | Phase 3 | Not yet recruiting | 356 | 2026-09-07 | 2026-09-15 |
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
HFA-152a, HFA-134a - Asthma | Phase 3 | Recruiting | 110 | 2026-09-01 | 2026-09-30 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | 370 | 2026-08-27 | 2026-09-30 |
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
GSK5784283, Placebo, Standard of care - Pulmonary Disease, Chronic Obstructive | Phase 3 | Recruiting | 624 | 2026-08-27 | 2026-09-09 |
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)
GSK5784283, Placebo, Standard of care - Asthma | Phase 3 | Recruiting | 514 | 2026-08-27 | 2026-09-25 |
A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma
tilrekimig, Placebo - Asthma | Phase 3 | Recruiting | 1100 | 2026-08-20 | 2026-10-30 |
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149 - Asthma | Phase 3 | Recruiting | 188 | 2026-08-04 | 2026-10-15 |
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Benralizumab - Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA) | Phase 3 | Recruiting | 230 | 2026-07-24 | 2026-10-27 |
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD
HSK39004 Inhalation Suspension, Placebo control - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | 387 | 2026-07-11 | 2026-06-22 |
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD
HSK39004 Inhalation Suspension - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Not yet recruiting | 300 | 2026-07-10 | 2026-06-08 |
Showing 20 of 1290. Sign in to see all of them.
Narrower conditions
Asthma (605) · Pulmonary Disease, Chronic Obstructive (542) · Bronchiolitis Obliterans Syndrome (86) · Lung Diseases (48) · Emphysema (34) · Bronchitis, Chronic (31) · Respiratory Tract Diseases (30) · Bronchitis (29) · Bronchiolitis (27) · Dyspnea (24) · Bronchial Diseases (20) · Hypersensitivity (15) · Bronchiolitis Obliterans (12) · Lymphoma, Follicular (12)
Broader conditions
Respiratory Tract Diseases (1260) · Lung Diseases (1242) · Bronchial Diseases (761) · Immune System Diseases (691) · Pathological Conditions, Signs and Symptoms (651) · Hypersensitivity, Immediate (606) · Respiratory Hypersensitivity (601) · Hypersensitivity (593) · Pathologic Processes (584) · Disease Attributes (573) · Chronic Disease (569) · Bronchitis (146) · Infections (112) · Bronchiolitis (97)
Interventions
Tiotropium Bromide (95) · Formoterol Fumarate (89) · Budesonide (87) · Albuterol (73) · Fluticasone (67) · Salmeterol Xinafoate (62) · Budesonide, Formoterol Fumarate Drug Combination (58) · indacaterol (40) · montelukast (39) · Beclomethasone (38) · Fluticasone-Salmeterol Drug Combination (38) · Glycopyrrolate (37) · fluticasone furoate (32) · olodaterol (26) · vilanterol (26)
Sponsors
AstraZeneca (177) · GlaxoSmithKline (127) · Boehringer Ingelheim (97) · Novartis Pharmaceuticals (74) · Chiesi Farmaceutici S.p.A. (38) · Organon and Co (36) · Sanofi (26) · Teva Branded Pharmaceutical Products R&D, Inc. (23) · Novartis (21) · Pearl Therapeutics, Inc. (19) · Pfizer (18) · Milton S. Hershey Medical Center (17) · Sumitomo Pharma America, Inc. (16) · Assistance Publique - Hôpitaux de Paris (12) · National Heart, Lung, and Blood Institute (NHLBI) (10)
Countries
United States (543) · Germany (295) · Canada (253) · Poland (213) · United Kingdom (204) · Spain (203) · France (188) · Hungary (170) · Russia (163) · Argentina (162) · Italy (162) · South Korea (147) · Japan (132) · Mexico (129) · Czechia (127)
Top investigators
Catherine Bonuccelli (11) · Esther Garcia, MD (11) · Colin Reisner, MD (9)
Results publications
PMID 36472162, PMID 32943047, PMID 35815359, PMID 27881132, PMID 31319851, PMID 42551404, PMID 24314123, PMID 32816215, PMID 39393433, PMID 20102307, PMID 28419462, PMID 29174062, PMID 30077810, PMID 30954640, PMID 32180164, PMID 32462607, PMID 32671684, PMID 32848381, PMID 42476723, PMID 21227674, PMID 21397482, PMID 22206353, PMID 22329608, PMID 24966061, PMID 24998880, PMID 25044280, PMID 25496316, PMID 25670896, PMID 26369589, PMID 26498386, PMID 26612545, PMID 26704701, PMID 27796912, PMID 28074135, PMID 29331313, PMID 29536781, PMID 30261995, PMID 30584583, PMID 30802500, PMID 31047111, PMID 31251094, PMID 31321713, PMID 31447130, PMID 31760132, PMID 32021148, PMID 32450869, PMID 32776202, PMID 33217063, PMID 33223095, PMID 34098955
NIH funding
2009 (23), 2023 (19), 2015 (16), 2008 (13), 2016 (13), 2014 (10), 2018 (10), 2017 (9), U10HL098115 (7), 2025 (6), U10HL074073 (5), U10HL074204 (5), U10HL074208 (5), U10HL074212 (5), U10HL074218 (5)